CHI3L1 and myeloid sarcoma: However, direct evidence of vitamin D–mediated CHI3L1 downregulation in MS is limited, and alternative mechanisms such as NF‐κB modulation, Nrf2 pathway activation, or indirect metabolic effects cannot be excluded.